Literature DB >> 11266595

The effect of substrate binding on the conformation and structural stability of Herpes simplex virus type 1 thymidine kinase.

C Wurth1, U Kessler, J Vogt, G E Schulz, G Folkers, L Scapozza.   

Abstract

The structure of Herpes simplex virus type 1 thymidine kinase (TK(HSV1)) is known at high resolution in complex with a series of ligands and exhibits important structural similarities to the nucleoside monophosphate (NMP) kinase family, which are known to show large conformational changes upon binding of substrates. The effect of substrate binding on the conformation and structural stability of TK(HSV1), measured by thermal denaturation experiments, far-UV circular dichroism (CD) and fluorescence is described, and the results indicate that the conformation of the ligand-free TK(HSV1) is less ordered and less stable compared to the ligated enzyme. Furthermore, two crystal structures of TK(HSV1) in complex with two new ligands, HPT and HMTT, refined to 2.2 A are presented. Although TK(HSV1):HPT does not exhibit any significant deviations from the model of TK(HSV1):dT, the TK(HSV1):HMTT complex displays a unique conformationally altered active site resulting in a lowered thermal stability of this complex. Moreover, we show that binding affinity and binding mode of the ligand correlate with thermal stability of the complex. We use this correlation to propose a method to estimate binding constants for new TK(HSV1)substrates using thermal denaturation measurements monitored by CD spectroscopy. The kinetic and structural results of both test substrates HPT and HMTT show that the CD thermal denaturation system is very sensitive to conformational changes caused by unusual binding of a substrate analog.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266595      PMCID: PMC2249856          DOI: 10.1110/ps.27401

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  36 in total

1.  Structural origins of high-affinity biotin binding to streptavidin.

Authors:  P C Weber; D H Ohlendorf; J J Wendoloski; F R Salemme
Journal:  Science       Date:  1989-01-06       Impact factor: 47.728

2.  Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.

Authors:  M E Black; T G Newcomb; H M Wilson; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

3.  Interaction of the recombinant herpes simplex virus type 1 thymidine kinase with thymidine and aciclovir: a kinetic study.

Authors:  S Kussmann-Gerber; C Wurth; L Scapozza; B D Pilger; V Pliska; G Folkers
Journal:  Nucleosides Nucleotides       Date:  1999-03

4.  Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine.

Authors:  A Prota; J Vogt; B Pilger; R Perozzo; C Wurth; V E Marquez; P Russ; G E Schulz; G Folkers; L Scapozza
Journal:  Biochemistry       Date:  2000-08-08       Impact factor: 3.162

5.  Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands.

Authors:  J N Champness; M S Bennett; F Wien; R Visse; W C Summers; P Herdewijn; E de Clerq; T Ostrowski; R L Jarvest; M R Sanderson
Journal:  Proteins       Date:  1998-08-15

6.  Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir.

Authors:  D G Brown; R Visse; G Sandhu; A Davies; P J Rizkallah; C Melitz; W C Summers; M R Sanderson
Journal:  Nat Struct Biol       Date:  1995-10

7.  Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.

Authors:  K W Culver; J Van Gilder; C J Link; T Carlstrom; T Buroker; W Yuh; K Koch; K Schabold; S Doornbas; B Wetjen
Journal:  Hum Gene Ther       Date:  1994-03       Impact factor: 5.695

8.  Movie of the structural changes during a catalytic cycle of nucleoside monophosphate kinases.

Authors:  C Vonrhein; G J Schlauderer; G E Schulz
Journal:  Structure       Date:  1995-05-15       Impact factor: 5.006

9.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

View more
  3 in total

1.  Testing the sensitivities of noncognate inhibitors to varicella zoster virus thymidine kinase: implications for postherpetic neuralgia therapy with existing agents.

Authors:  Lianjuan Yang; Xiaohui Mo; Hong Yang; Hejun Dai; Fei Tan
Journal:  J Mol Model       Date:  2014-06-25       Impact factor: 1.810

2.  Crystal structure of poxvirus thymidylate kinase: an unexpected dimerization has implications for antiviral therapy.

Authors:  Christophe Caillat; Dimitri Topalis; Luigi A Agrofoglio; Sylvie Pochet; Jan Balzarini; Dominique Deville-Bonne; Philippe Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

3.  Discovery of first-in-class nanomolar inhibitors of heptosyltransferase I reveals a new aminoglycoside target and potential alternative mechanism of action.

Authors:  Jozafina Milicaj; Bakar A Hassan; Joy M Cote; Carlos A Ramirez-Mondragon; Nadiya Jaunbocus; Angelika Rafalowski; Kaelan R Patel; Colleen D Castro; Ramaiah Muthyala; Yuk Y Sham; Erika A Taylor
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.